Immunotherapy in leukaemia  

作　　者：Xingmei Mu Chumao Chen Loujie Dong Zhaowei Kang Zhixian Sun Xijie Chen Junke Zheng Yaping Zhang 

机构地区：[1]Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Key Laboratory of Cell Differentiation and Apoptosis of Chinese inistry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [2]Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China

出　　处：《Acta Biochimica et Biophysica Sinica》2023年第6期974-987,共14页生物化学与生物物理学报（英文版）

基　　金：supported by the grants from the National Basic Research Program of China(Nos.2019YFA0801800 and 2018YFA0107000);the National Natural Science Foundation of China(Nos.81825001 and 32030030);the Innovative Group of NSFC(No.81721004);the Shanghai Science and Technology Commission(Nos.19XD1422100,20ZR1430900,20JC1410100 and 20204Y0008);the CAMS Innovation Fund for Medical Sciences(CIFMS)(2019-12M-5-051)as well as the Fundamental Research Funds for the Central Universities.

摘　　要：Leukaemia is the common name for a group of malignant diseases of the haematopoietic system with complex classifications and characteristics.Remarkable progress has been made in basic research and preclinical studies for acute leukaemia compared to that of the many other types/subtypes of leukaemia,especially the exploration of the biological basis and application of immunotherapy in acute myeloid leukaemia(AML)and B-cell acute lympho-blastic leukaemia(B-ALL).In this review,we summarize the basic approaches to immunotherapy for leukaemia and focus on the research progress made in immunotherapy development for AML and ALL.Importantly,despite the advances made to date,big challenges still exist in the effectiveness of leukaemia immunotherapy,especially in AML.Therefore,we use AML as an example and summarize the mechanisms of tumour cell immune evasion,describe recently reported data and known therapeutic targets,and discuss the obstacles in finding suitabie treatment targets and the results obtained in recent clinical trials for several types of single and combination immunotherapies,such as bispecific antibodies,cell therapies(CAR-T-cell treatment),and checkpoint blockade.Finally,we summarize novel immunotherapy strategies for treating lymphocytic leukaemia and clinical trial results.

关 键 词：ACUTE CLINICAL IMMUNOTHERAPY 

分 类 号：R730.51[医药卫生—肿瘤]